Missouri is currently home to 2003 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
Recruiting
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Gender:
All
Ages:
Between 22 months and 42 months
Trial Updated:
11/22/2022
Locations: St. Louis University, Saint Louis, Missouri
Conditions: Neurodevelopmental Abnormality
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer
Recruiting
This is a phase 1/2a, first-in-human study to evaluate the safety and tolerability of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/18/2022
Locations: Washington University School of Medicine in St. Louis, Saint Louis, Missouri
Conditions: Metastatic Castration Resistant Prostate Cancer
TruGraf® Long-term Clinical Outcomes Study
Recruiting
This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Primary Coordinator Coordinator, Saint Louis, Missouri
Conditions: Kidney Transplant Rejection
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: Washington University, Saint Louis, Missouri
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
All
Ages:
All
Trial Updated:
11/04/2022
Locations: Washington University Medical Center/ St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Congenital Diaphragmatic Hernia
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Recruiting
To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Clinical Research Professionals, Chesterfield, Missouri
Conditions: Diabetic Peripheral Neuropathy
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
Recruiting
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy participants aged 18 to 65 years. The study will be conducted in three parts (Part A, an optional Part B and Part C).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/02/2022
Locations: Investigative Site, Saint Louis, Missouri
Conditions: Covid19
HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)
Recruiting
The Hydrocephalus Clinical Research Network (HCRN) has been established by philanthropic funding to conduct multi-institutional research (clinical trials and observational studies) on pediatric hydrocephalus. In addition to philanthropic funding, the HCRN has also received an NIH NINDS Challenge Grant to support the network infrastructure which allows for the conduct of this and other network studies. The HCRN consists of multiple Clinical Centers and the Data Coordinating Center (DCC). The HCRN... Read More
Gender:
All
Ages:
18 years and below
Trial Updated:
11/02/2022
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pediatric Hydrocephalus
Irrisept Trauma Study
Recruiting
Early debridement and definitive fixation, at the initial operative setting, historically led to no difference in the infection rates for Gustilo-Anderson type III open tibia fractures. However, Lenarz et al. reported that delaying definitive fixation in open tibia fractures could decrease the deep infection rate. At the University of Missouri, the investigators found that staged procedures, including initial debridement-temporary fixation and delayed definitive fixation, did not statistically d... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2022
Locations: University of Missouri Health System, Columbia, Missouri
Conditions: Gustilo-Anderson Type III Open Tibia Fracture
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
Recruiting
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: Clinical Research Consultants, Kansas City, Missouri
Conditions: Hyperkalemia
MyLeukoMAP™ Genomic Survival Prediction Assay Pivotal Clinical Study
Recruiting
The MyLeukoMAP™ Pivotal Clinical Study will assess the accuracy of MyLeukoMAP™, a new molecular blood test, performed within 30 days before scheduled surgical / interventional therapies for Heart Failure, to determine its effectiveness in improving clinical decision support by providing a quantitative prediction of low, indeterminate, or high risk of death one year after surgical / interventional therapies that is not identified by current diagnostic tools.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Heart Failure